Which of the following has activity against Methicillin-Resistant Staphylococcus aureus (MRSA)?

Rationale: A. Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit. This unique mechanism makes it highly effective against resistant Gram-positive pathogens, including MRSA and vancomycin-resistant enterococci (VRE). It is often utilized for skin and soft tissue infections or pneumonia when other MRSA-active agents are contraindicated or have failed to produce results. B. Vancomycin is a glycopeptide antibiotic that has long been considered the primary gold standard for treating severe systemic MRSA infections. It works by inhibiting bacterial cell wall synthesis through binding to the D-alanyl-D-alanine portion of the peptidoglycan precursor. While it requires therapeutic drug monitoring to prevent nephrotoxicity, it remains a cornerstone in the pharmacological management of methicillin-resistant staphylococcal endocarditis, osteomyelitis, and bacteremia. C. Clindamycin is a lincosamide antibiotic that can be used for less severe, community-acquired MRSA infections, particularly in skin and soft tissue cases. It functions by inhibiting the 50S ribosomal subunit, thereby preventing bacterial protein chain elongation. However, clinicians must perform a D-test to ensure the specific MRSA strain does not have inducible resistance to clindamycin before relying on it for definitive clinical therapy. D. All of these medications possess distinct mechanisms of action that allow them to overcome the penicillin-binding protein mutations that characterize methicillin resistance in staphylococci. Whether through cell wall inhibition, such as vancomycin, or protein synthesis inhibition, such as linezolid and clindamycin, each agent provides a therapeutic option for MRSA. The choice between them depends on the infection's severity, the patient's allergy profile, and local susceptibility patterns.